Researchers at Toyohashi University of Technology have built a semiconductor microchip that can detect extraordinarily small amounts of disease markers in bodily fluids, potentially bringing lab-grade sensitivity to portable diagnostic devices. The team, led by Associate Professor Kazuhiro Takahashi with master's student Tomoya Maeda and colleagues in electrical and electronic information engineering, focused on tumor markers, the molecules whose presence or concentration can signal disease. In their demonstration, the chip detected the prostate cancer marker PSA at levels as low as 100 attograms in one milliliter of fluid, an amount so tiny it approaches the performance of much larger laboratory systems. What makes the device notable is not just its sensitivity, but how it works: instead of relying on dyes or other labels to create a readable signal, it directly converts molecular interactions into mechanical motion on the chip. The heart of the system is a deformable nanosheet, an extremely thin film that bends when target molecules attach to its surface. By refining how that sensing layer is made, the researchers produced a thinner, more uniform, and less damaged chip than earlier versions. The study, published in Sensors, points toward a future in which high-performance biomarker testing could happen on small, low-cost semiconductor devices. That could matter not only for cancer screening, but also for monitoring infections and other conditions where subtle changes in blood or saliva markers reveal what is happening in the body.
How the chip senses disease markers
The device works by capturing specific molecules from blood, saliva, or other bodily fluids on the surface of a flexible sensing layer. When those molecules stick to the surface, they create tiny forces that slightly deform the nanosheet, and the chip reads that deformation as a signal.
This is a form of label-free detection, meaning the test does not need fluorescent tags, colored chemicals, or other added markers to show that binding has happened. That matters because label-free systems can simplify testing, reduce preparation steps, and make miniaturized devices easier to build.
Why PSA was an important test case
For their proof-of-concept, the team targeted PSA, or prostate-specific antigen, a protein commonly measured in blood tests related to prostate cancer. PSA is already widely used in clinical screening, so it provides a familiar benchmark for judging whether a new sensor platform is practically useful.
The researchers reported that the chip detected as little as 100 attograms of PSA in one milliliter of fluid. An attogram is one quintillionth of a gram, so the amount involved is almost unimaginably small; in molar terms, the team says this corresponds to about three attomolar, which is an extremely low concentration.
A manufacturing change made the difference
A key part of the advance came from changing how the sensor's functional layer was fabricated. The researchers moved away from a conventional approach and instead used chemical vapor deposition, a common semiconductor manufacturing method in which a thin material layer is formed from vapor-phase chemicals.
That shift produced a sensing layer that was thinner, more even, and less degraded. In plain terms, the chip became more consistent and more delicate in the right way, helping it respond more reliably to the very small physical forces generated when biomarker molecules attach to the surface.
Why this compares well with larger machines
Modern biomarker tests often rely on labeling agents that create a color change or other optical signal, which is then read by relatively large instruments. Those systems can be highly sensitive, but they often require extra reagents, more complex workflows, and equipment that is better suited to centralized labs than point-of-care settings.
The Toyohashi team says its detection limit is comparable to large testing devices that use labeling agents. If that performance can be translated into robust commercial hardware, it would suggest that portable chips may eventually handle tests that today still depend on bulkier laboratory platforms.
Beyond prostate cancer
Although the demonstration centered on a prostate cancer marker, the broader idea is more flexible. Many diseases are associated with distinct patterns of biomarkers, and a chip that can sensitively measure tiny quantities of those molecules could be adapted for a wide range of conditions.
The researchers point to COVID-19 as one example. Reports have shown that patients with severe cases can have different concentrations of multiple biomarkers in their blood compared with people who have milder disease, raising the possibility that such measurements could help predict how ill a patient may become.
Why less invasive testing matters
Biomarker analysis is not limited to blood draws. The article notes that saliva-based screening is also being explored as a less invasive way to assess cancer risk, and compact semiconductor sensors could fit naturally into that trend.
That is important because easier sampling usually means testing can be done more often and by more people. A sensor that works with small fluid volumes and avoids complicated preparation steps could help move diagnostics closer to clinics, pharmacies, or even home use.
Why This Matters
This work sits at the intersection of semiconductor engineering and medicine, which is exactly where many next-generation diagnostics are being built. By using micromachine fabrication methods to create a chip that translates molecular binding into physical motion, the researchers show that sophisticated biological measurements do not always need big optical systems or elaborate chemistry.
If the approach proves reliable outside the lab, it could support earlier cancer detection, more convenient screening, and faster assessment of infectious or inflammatory diseases. The biggest promise is not just sensitivity, but accessibility: bringing ultra-sensitive testing into smaller, cheaper, and more deployable formats.
What comes next
The next challenge will be turning a strong laboratory result into a practical diagnostic product. That means showing the chip can operate consistently with real-world patient samples, distinguish target markers from similar molecules, and eventually measure multiple biomarkers at once.
Even so, the underlying result is striking: a tiny semiconductor device has shown it can detect vanishingly small traces of a clinically important biomarker. As biosensors continue to borrow tools from the chip industry, the line between electronics and diagnostics is likely to get thinner, faster, and far more useful.